The report on the global enzyme-linked immunosorbent assay (ELISA) testing market provides qualitative and quantitative analysis for the period from 2021-2030. The global enzyme-linked immunosorbent assay (ELISA) testing market was valued at USD 2.47 billion in 2022 and is expected to reach USD 3.66 billion in 2030, with a CAGR of more than 5.09% during the forecast period 2023-2030. The study on enzyme-linked immunosorbent assay (ELISA) testing market covers the analysis of the leading geographies such as North America, Europe, Asia Pacific, and RoW for the period of 2021-2030.
Enzyme-linked immunosorbent assay (ELISA) testing is a laboratory technique used to detect and quantify specific proteins, such as antibodies or antigens, in a sample by using antibodies that bind to the target protein and a color-changing reaction for detection. The surge in global cancer cases has become a primary driver of the enzyme-linked immunosorbent assay (ELISA) testing market's expansion. Factors contributing to increased cancer rates include lifestyle choices like smoking and poor dietary habits, environmental influences like pollution and radiation exposure, an aging population, and genetic disorders. According to the World Health Organization, cancer was responsible for nearly 10 million deaths in 2020, highlighting its global impact. ELISA plays a crucial role in cancer diagnosis and monitoring by enabling precise detection and quantification of cancer-related biomarkers, facilitating early detection, accurate prognosis, and treatment evaluation. Consequently, ELISA tests are in high demand in healthcare and research. Additionally, the market is benefiting from the rising prevalence of infectious diseases, including HIV, dengue, hepatitis, malaria, and influenza. In 2020, approximately 37.7 million people were living with HIV worldwide, as per WHO data from July 2022. This growing disease burden underscores the demand for diagnostic tools like ELISA tests.
The "Sandwich ELISA" segment of the enzyme-linked immunosorbent assay (ELISA) testing market commands the largest market share. Sandwich ELISA is a type of enzyme-linked immunosorbent assay (ELISA) that is used to detect and quantify antigens in a sample. It is one of the most sensitive and widely used immunoassay techniques. Furthermore, A significant driving factor for ELISA testing's widespread adoption is its exceptional sensitivity, enabling the detection of minute antigen levels in samples. Its specificity allows the precise identification of target antigens, even amidst other substances, while its quantitative capabilities provide accurate antigen quantification. Additionally, the simplicity of ELISA procedures, compatible with diverse equipment and reagents, makes it an accessible and versatile choice for diagnostics and research, further fueling its popularity. Sand which ELISA testing is used to diagnose a wide range of diseases, including HIV, hepatitis, and cancer. Therefore, owing to the increasing prevalence of both communicable and non-communicable diseases the Sandwich ELISA segment is anticipated to hold largest market share in the ELISA market.
The North America region is poised to hold the largest market share in the global enzyme-linked immunosorbent assay (ELISA) testing market. The prominent position of North America in the global ELISA testing market can be ascribed to the escalating incidence of chronic illnesses, infectious diseases, and a growing elderly population. Notably, the National Center for Chronic Disease Prevention reports that 4 out of 10 American adults grapple with two or more chronic conditions, creating a sustained need for ELISA tests and driving market growth. Furthermore, substantial R&D investments from government bodies and pharmaceutical companies, particularly in the study of chronic diseases and diabetes, are pivotal factors fueling the regional market. For instance, the Pharmaceutical Research and Manufacturers of America disclosed that the biopharmaceutical industry channeled approximately USD 102.3 billion into research and development in 2021. Additionally, North America's robust healthcare infrastructure and emphasis on cutting-edge medical diagnostics significantly contribute to the demand for ELISA testing.
1. Key Opinion Leaders
2. Internal and External subject matter experts
3. Professionals and participants from the industry
2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/ country managers
5. Vice President level executives.
2. Government/institutional publications
3. Trade and associations journals
4. Databases such as WTO, OECD, World Bank, and among others.
5. Websites and publications by research agencies
2. Complete coverage of all the segments in the enzyme-linked immunosorbent assay (ELISA) testing market to analyze the trends, developments in the global market and forecast of market size up to 2030.
3. Comprehensive analysis of the companies operating in the global enzyme-linked immunosorbent assay (ELISA) testing market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
4. Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.
Enzyme-linked immunosorbent assay (ELISA) testing is a laboratory technique used to detect and quantify specific proteins, such as antibodies or antigens, in a sample by using antibodies that bind to the target protein and a color-changing reaction for detection. The surge in global cancer cases has become a primary driver of the enzyme-linked immunosorbent assay (ELISA) testing market's expansion. Factors contributing to increased cancer rates include lifestyle choices like smoking and poor dietary habits, environmental influences like pollution and radiation exposure, an aging population, and genetic disorders. According to the World Health Organization, cancer was responsible for nearly 10 million deaths in 2020, highlighting its global impact. ELISA plays a crucial role in cancer diagnosis and monitoring by enabling precise detection and quantification of cancer-related biomarkers, facilitating early detection, accurate prognosis, and treatment evaluation. Consequently, ELISA tests are in high demand in healthcare and research. Additionally, the market is benefiting from the rising prevalence of infectious diseases, including HIV, dengue, hepatitis, malaria, and influenza. In 2020, approximately 37.7 million people were living with HIV worldwide, as per WHO data from July 2022. This growing disease burden underscores the demand for diagnostic tools like ELISA tests.
The "Sandwich ELISA" segment of the enzyme-linked immunosorbent assay (ELISA) testing market commands the largest market share. Sandwich ELISA is a type of enzyme-linked immunosorbent assay (ELISA) that is used to detect and quantify antigens in a sample. It is one of the most sensitive and widely used immunoassay techniques. Furthermore, A significant driving factor for ELISA testing's widespread adoption is its exceptional sensitivity, enabling the detection of minute antigen levels in samples. Its specificity allows the precise identification of target antigens, even amidst other substances, while its quantitative capabilities provide accurate antigen quantification. Additionally, the simplicity of ELISA procedures, compatible with diverse equipment and reagents, makes it an accessible and versatile choice for diagnostics and research, further fueling its popularity. Sand which ELISA testing is used to diagnose a wide range of diseases, including HIV, hepatitis, and cancer. Therefore, owing to the increasing prevalence of both communicable and non-communicable diseases the Sandwich ELISA segment is anticipated to hold largest market share in the ELISA market.
The North America region is poised to hold the largest market share in the global enzyme-linked immunosorbent assay (ELISA) testing market. The prominent position of North America in the global ELISA testing market can be ascribed to the escalating incidence of chronic illnesses, infectious diseases, and a growing elderly population. Notably, the National Center for Chronic Disease Prevention reports that 4 out of 10 American adults grapple with two or more chronic conditions, creating a sustained need for ELISA tests and driving market growth. Furthermore, substantial R&D investments from government bodies and pharmaceutical companies, particularly in the study of chronic diseases and diabetes, are pivotal factors fueling the regional market. For instance, the Pharmaceutical Research and Manufacturers of America disclosed that the biopharmaceutical industry channeled approximately USD 102.3 billion into research and development in 2021. Additionally, North America's robust healthcare infrastructure and emphasis on cutting-edge medical diagnostics significantly contribute to the demand for ELISA testing.
Report Findings
1) Drivers
- The rising prevalence of various diseases, including infectious diseases, autoimmune disorders, and cancer, is driving the demand for ELISA testing as it offers accurate and reliable diagnostic results.
- Growth in life sciences research, spanning drug discovery, biomarker identification, and genomics, directly fuels ELISA market expansion.
2) Restraints
- Elisa market faces competition from faster, more sensitive alternatives like PCR, next-gen sequencing, and crispr-based assays. Its cost and complexity restrict accessibility, prompting researchers to seek cost-effective alternatives.
3) Opportunities
- The growing trend towards personalized medicine and targeted therapies presents a significant opportunity to meet increased demand for custom ELISA tests designed to align with specific patient profiles and treatment strategies.
Research Methodology
A) Primary Research
The primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include1. Key Opinion Leaders
2. Internal and External subject matter experts
3. Professionals and participants from the industry
The primary research respondents typically include
1. Executives working with leading companies in the market under review2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/ country managers
5. Vice President level executives.
B) Secondary Research
Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. Each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.The secondary sources of the data typically include
1. Company reports and publications2. Government/institutional publications
3. Trade and associations journals
4. Databases such as WTO, OECD, World Bank, and among others.
5. Websites and publications by research agencies
Segment Covered
The global enzyme-linked immunosorbent assay (ELISA) testing market is segmented on the basis of type, application, and end user.The Global Enzyme-linked Immunosorbent Assay (ELISA) Testing Market by Type
- Direct ELISA
- Sandwich ELISA
- Indirect ELISA
- Multiple and Portable ELISA
- Competitive ELISA
The Global Enzyme-linked Immunosorbent Assay (ELISA) Testing Market by Application
- Immunology
- Inflammation
- Infectious Diseases
- Cancer, Protein Quantitation
- Others Applications
The Global Enzyme-linked Immunosorbent Assay (ELISA) Testing Market by End User
- Hospitals
- Clinical Laboratories
- Pharmaceutical Companies
- Biotechnological Companies
- Research and Academic Institute
- Others
Company Profiles
The companies covered in the report include- Agilent Technologies, Inc
- Thermo Fisher Scientific Inc.
- Ortho Clinical Diagnostics
- Thermo Fisher Scientific Inc.
- ZEUS Scientific, Inc.
- Abcam plc.
- bioMérieux
- Neogen Corporation
- Bio-Rad Laboratories, Inc.
- Bio-Techne
What does this Report Deliver?
1. Comprehensive analysis of the global as well as regional markets of the enzyme-linked immunosorbent assay (ELISA) testing market.2. Complete coverage of all the segments in the enzyme-linked immunosorbent assay (ELISA) testing market to analyze the trends, developments in the global market and forecast of market size up to 2030.
3. Comprehensive analysis of the companies operating in the global enzyme-linked immunosorbent assay (ELISA) testing market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
4. Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Preface
Chapter 2. Executive Summary
Chapter 3. Global Enzyme-linked Immunosorbent Assay (ELISA) Testing Market Overview
Chapter 5. Company Profiles and Competitive Landscape
Chapter 6. Global Enzyme-linked Immunosorbent Assay (ELISA) Testing Market by Type
Chapter 7. Global Enzyme-linked Immunosorbent Assay (ELISA) Testing Market by Application
Chapter 8. Global Enzyme-linked Immunosorbent Assay (ELISA) Testing Market by End User
Chapter 9. Global Enzyme-linked Immunosorbent Assay (ELISA) Testing Market by Region 2023-2030
Companies Mentioned
- Agilent Technologies, Inc
- Thermo Fisher Scientific Inc.
- Ortho Clinical Diagnostics
- Thermo Fisher Scientific Inc.
- ZEUS Scientific, Inc.
- Abcam plc.
- bioMérieux
- Neogen Corporation
- Bio-Rad Laboratories, Inc.
- Bio-Techne
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 255 |
| Published | March 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 2.47 Billion |
| Forecasted Market Value ( USD | $ 3.66 Billion |
| Compound Annual Growth Rate | 5.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
